Assessing Undertreatment and Misuse of ADHD Medications on Four Continents

Children and adolescents with ADHD come into contact with child welfare services (CWS) far more often than their peers. There are many contributing factors to consider, including the fact that hyperactivity and impulsivity frequently lead to behaviors that are considered disruptive and cause academic and social difficulties. Many of these children are also growing up in households marked by parental conflict and/or single-parent arrangements.  All of these circumstances can compound vulnerability and, historically, increase the likelihood of CWS involvement.

Background: 

In Norway, Child Welfare Services operate at the municipal level and are legally required in every local authority. Their scope spans investigation, family support, and, where necessary, out-of-home placement and ongoing monitoring. Grounds for intervention include abuse, neglect, behavioral or psychosocial difficulties, and inadequate care-giving. Norwegian CWS works closely with health, education, and social services and places a strong emphasis on keeping families together. Compared with systems in countries such as the United States, Poland, Romania, and the Czech Republic, the Norwegian approach sets a lower bar for intervention and leans toward home-based support, while setting a higher bar for out-of-home placements. This model is shared by other Nordic countries, as well as Germany and the United Kingdom. 

Research into whether ADHD medication affects child welfare caseloads is remarkably sparse. A single Danish study previously found that medication treatment accounted for much of an observed decline in foster care cases, but no study had examined medication’s broader impact on CWS involvement, covering both supportive interventions and out-of-home placements. 

Norway’s universal single-payer health system and comprehensive national registers make population-wide research of this kind feasible. Drawing on these resources, a Norwegian research team set out to test whether ADHD medication reduces children’s contact with CWS and their need for out-of-home placement. 

The Study:

This study included all 5,930 children and adolescents aged 5 to 14 who received a clinical ADHD diagnosis from Child and Adolescent Mental Health Services between 2009 and 2011. Each was followed for up to 4 years post-diagnosis, the upper age limit being 18, at which point CWS jurisdiction ends. This group was compared with more than 53,000 peers who had no CWS contact during the same period. 

The results showed a meaningful, though not dramatic, association between medication and reduced CWS contact. At one year, treated children had approximately 7% fewer contacts with CWS; by two years, that figure had risen to around 12%. The effect then narrowed, settling at roughly 7–8% reductions at the three- and four-year marks. 

The picture for out-of-home placements is considerably less convincing. The research team highlighted a 3% reduction at two-year follow-up, but this finding barely crossed the threshold of statistical significance, and no effect was observed at the one-, three-, or four-year follow-up points. 

The Take-Away:

The authors concluded that pharmacological treatment for ADHD is associated with reductions in both supportive CWS services and out-of-home placements among children affected by clinicians’ prescribing decisions in Norway. A more cautious reading of the same data, however, would emphasize an overall reduction in CWS contact of roughly 8%, while treating the out-of-home placement finding as, at best, inconclusive. 

‍

Stimulant medications, such as methylphenidate (Ritalin) and amphetamines (Adderall),  are among the most widely prescribed drugs in the world. In the United States alone, prescription rates have climbed more than 50% over the past decade, driven largely by growing awareness of ADHD in both children and adults. Yet stimulants also have a long history of non-medical use, and concerns about their psychological risks persist among patients, families, and clinicians alike. 

Two major studies now offer the clearest picture yet of what that risk actually looks like, and who it may affect.

‍

The Background: 

Before turning to the research, it helps to understand the landscape. A notable share of stimulant users misuse their medication: roughly one in four takes it in ways other than prescribed, and about one in eleven meets criteria for Prescription Stimulant Use Disorder (PSUD). Counterintuitively, most people with PSUD aren’t obtaining drugs illicitly — they’re misusing their own prescriptions. 

This distinction between therapeutic and non-therapeutic use turns out to be critical when evaluating psychosis risk. 

The Study: 

A comprehensive meta-analysis by Jangra and colleagues pooled data across more than a dozen studies to compare psychotic outcomes in people using stimulants therapeutically versus non-therapeutically. The contrast was striking. 

Among therapeutic users  (more than 220,000 individuals taking stimulants at prescribed doses under medical supervision), psychotic episodes occurred in roughly one in five hundred people. When symptoms did appear, they typically emerged after prolonged treatment or in individuals with pre-existing psychiatric vulnerabilities, and they usually resolved when the medication was stopped. 

Among non-therapeutic users  (over 8,000 participants across twelve studies, many using methamphetamine or high-dose amphetamines), nearly one in three experienced psychotic symptoms. These episodes tended to be more severe, involving persecutory delusions and hallucinations, with faster onset and a greater likelihood of recurrence or persistence. 

The biology underlying this difference is well understood. When stimulants are taken orally at guideline-recommended doses, they produce moderate, gradual changes in neurotransmitter activity central to attention and executive functions. The brain tolerates these changes relatively well. Non-therapeutic use, by contrast, often involves much higher doses that are frequently delivered through non-oral routes such as injection or smoking. This produces a rapid, excessive surge in dopamine activity, which is precisely the neurochemical pattern associated with psychotic symptoms. 

The takeaway here is not that therapeutic stimulant use is risk-free, but that risk is strongly modulated by dose, route of administration, and individual psychiatric history. Clinicians are advised to monitor patients with pre-existing mood or psychotic disorders, particularly carefully. 

A Nationwide Study Focuses on Methylphenidate Specifically:

Where the meta-analysis cast a wide net, a large-scale population study by Healy and colleagues drilled into a specific and clinically pressing question: does methylphenidate (the most commonly prescribed ADHD medication, also known as Ritalin) increase the risk of developing a psychotic disorder? 

To find out, the researchers analyzed Finland's national health insurance database, tracking nearly 700,000 individuals diagnosed with ADHD. Finland's single-payer system made this kind of comprehensive, long-term tracking possible in a way that fragmented healthcare systems rarely allow. 

Critically, the team adjusted for a range of confounding factors that have clouded previous research, including sex, parental education, parental history of psychosis, and the number of psychiatric visits and diagnoses prior to the ADHD diagnosis itself (a proxy for illness severity). After these adjustments, they found no significant difference in the risk of schizophrenia or non-affective psychosis between patients treated with methylphenidate and those who remained unmedicated. This held true even among patients with four or more years of continuous methylphenidate use. 

The Take-Away: 

When considered together, these studies offer meaningful reassurance without encouraging complacency. 

For patients and families weighing ADHD treatment, the evidence suggests that methylphenidate used as prescribed does not increase psychosis risk, even over years of use. The rare cases of stimulant-associated psychosis in therapeutic settings are typically linked to high doses, pre-existing vulnerabilities, or both, and tend to resolve with discontinuation. 

For clinicians, the findings reinforce the importance of baseline psychiatric assessment before initiating stimulant therapy, ongoing monitoring in patients with mood or psychotic disorder histories, and clear patient education about the risks of dose escalation or non-oral use. 

The picture that emerges is one of a meaningful distinction between a medication used carefully within its therapeutic window and a drug misused outside of it. This distinction matters enormously when communicating risk to patients, policymakers, and the public. 

‍

ADHD is commonly treated with medication, but these treatments frequently cause side effects such as reduced appetite and disrupted sleep. Psychological and behavioral therapies exist as alternatives, but they tend to be expensive, hard to scale, and generally do little to address the motor difficulties that many children with ADHD experience — things like clumsy movement, poor handwriting, or difficulty with coordination. 

Physical exercise has attracted attention as a more accessible option. But research findings have been mixed, partly because studies vary so widely in how exercise is delivered and what outcomes they measure. This meta-analysis, drawing on 21 studies involving 850 children and adolescents aged 5–20 with a clinical ADHD diagnosis, tries to cut through that noise. 

Two types of motor skills 

The researchers separated motor skills into two broad categories: 

• Gross motor skills — movements involving large muscle groups, such as running, jumping, throwing, and maintaining balance 

• Fine motor skills — precise, controlled movements, typically of the hands and fingers, such as handwriting and manual dexterity (the ability to handle objects skillfully) 

‍

The Data: 

Gross motor skills (16 studies, 613 participants) 

Overall, exercise produced medium-to-large improvements in gross motor skills. The strongest gains were in: 

• Object control (e.g., throwing, kicking) — large improvement 

• Locomotion (e.g., running, swimming), body coordination, and strength — medium improvements 

No significant gains were found in balance or flexibility. 

Fine motor skills (13 studies, 553 participants):

Exercise also produced medium-to-large improvements in fine motor skills, specifically: 

• Handwriting: large improvement 

• Manual dexterity: medium-to-large improvement 

• Hand-eye coordination: moderate improvement 

The Results: What Kind of Exercise Works Best? 

Two factors stood out consistently across both gross and fine motor skills: session length and frequency. 

• Sessions longer than 45 minutes produced roughly twice the benefit of shorter sessions 

• Three or more sessions per week outperformed less frequent programs for gross motor gains 

The type of exercise mattered; structured programs with clear motor-skill components (rather than unstructured physical activity) yielded stronger results. 

These results are not without caveats, however. The authors urge caution in interpreting these findings. A few key limitations include: 

• Potential Publication Bias:  Studies showing positive results are more likely to be published, which can inflate apparent benefits. For gross motor skills, adjusting for this bias reduced the effect size from medium-to-large,  to medium. 

• Active vs. Passive Controls: When exercise was compared against doing nothing (a passive control), improvements looked significant. When compared against regular school activities (an active control), the gains were no longer statistically significant. This is a meaningful distinction: it suggests exercise may be beneficial, but not dramatically more so than simply being physically active in a structured school setting. 

• Medication status: Most participants were taking ADHD medication, so it’s unclear how well these findings apply to unmedicated children who might stand the most to benefit from structured exercise. 

• Study quality: Many studies lacked proper randomization, weakening confidence in the conclusions. 

The Bottom Line 

This meta-analysis provides tentative moderate evidence that structured physical exercise can meaningfully support motor skill development in children and adolescents with ADHD — particularly when sessions run longer than 45 minutes and occur at least three times a week. The benefits appear most robust for object control, locomotion, handwriting, and manual dexterity. 

That said, the evidence base still has real gaps. The authors call for better-designed, fully randomized controlled trials with consistent methods, standardized ways of measuring exercise intensity, and greater inclusion of children and adolescents who are not on medication — all of which would help clarify when, how, and for whom exercise works best. 

‍